Scancell Holdings (SCLP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 10.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 20.50
  • 52 Week Low: 8.15
  • Currency: UK Pounds
  • Shares Issued: 927.82m
  • Volume: 239,636
  • Market Cap: £95.10m

Scancell losses widen on expense of ongoing trials

By Josh White

Date: Friday 28 Oct 2022

LONDON (ShareCast) - (Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.
The AIM-traded firm said its cash balance at year-end on 30 April totalled £28.7m, down from £41.1m at the end of the 2021 period.

It said its capital structure was improved during the year, through the extension of the redemption dates of the outstanding unsecured convertible loan notes it issued in 2020.

On the operational front, Scancell said it expanded its research and development capabilities by taking new laboratory and office space in the Bellhouse Building at the Oxford Science Park.

It also confirmed that board director Dr Richard Goodfellow had decided to retire, and not to stand for re-election at the upcoming annual general meeting.

"It has been a year of strong operational and clinical progress for Scancell with three vaccine candidates now in the clinic and the antibody platforms gathering momentum with expanded internal research and external validation," said chief executive officer Lindy Durrant.

"We recently initiated cohort 2 of the Modi-1 clinical trial, the first candidate from our Moditope platform, and anticipate reporting early safety and efficacy data from the ModiFY study in the next 12 months.

"In addition, we continue to progress SCOPE for SCIB1, and have completed recruitment in our COVIDITY phase 1 trial in South Africa."

Professor Durrant said it was also a "transformational period" for its antibody technology, culminating in the post-period signing of a licensing agreement with Genmab, providing "strong commercial validation" of Scancell's scientific approach.

"Scancell is one of only a few companies globally which has the capability to produce high affinity, humanised anti-glycan antibodies and the board remains excited for what the future holds for this platform."

At 1417 BST, shares in Scancell Holdings were up 5.27% at 15.95p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

SCLP Market Data

Currency UK Pounds
Share Price 10.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 20.50
52 Week Low 8.15
Volume 239,636
Shares Issued 927.82m
Market Cap £95.10m

SCLP Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
7.41% below the market average7.41% below the market average7.41% below the market average7.41% below the market average7.41% below the market average
3.70% above the sector average3.70% above the sector average3.70% above the sector average3.70% above the sector average3.70% above the sector average
Price Trend
51.09% below the market average51.09% below the market average51.09% below the market average51.09% below the market average51.09% below the market average
12.28% above the sector average12.28% above the sector average12.28% above the sector average12.28% above the sector average12.28% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

SCLP Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:14 96 @ 10.38p
15:40 1,000 @ 10.00p
14:38 50,000 @ 10.44p
14:02 5,000 @ 10.18p
13:33 27,932 @ 10.15p

SCLP Key Personnel

CEO Lindy Durrant
CFO Sath Nirmalananthan

Top of Page